Prostate cancer is the most frequent noncutaneous cancer occurring in men. On average,
men with localized prostate cancer have a high 10-year survival rate, and many can be …

Targeted radionuclide therapy (TRT) uses radiopharmaceuticals to specifically irradiate
tumor cells while sparing healthy tissue. Response to this treatment highly depends on the …

Prostate cancer is the second most frequent malignancy in men worldwide. Unfortunately,
current therapies often lead to the onset of metastatic castration-resistant prostate cancer …

Introduction Despite FDA approval of sipuleucel-T in 2010, endeavors to use immune
checkpoint inhibitors in unselected prostate cancer patients have not improved clinical …

Radionuclide therapy with nano-sized carriers is a very promising approach to treat various
types of cancer. The preparation of radioactive nanocarriers can be achieved with minimum …

We have previously investigated the biodistribution and therapy effect of a humanized
monoclonal antibody targeting free prostate-specific antigen (fPSA) intended for theranostics …

Purpose. Nanoparticles (NPs) with radioactive atoms incorporated within the structure of the
NP or bound to its surface, functionalized with biomolecules are reported as an alternative to …

In radiopharmaceutical therapy, intratumoral uptake of radioactivity usually leads to
heterogeneous absorbed dose distribution. The likelihood of treatment success can be …

Abstract We performed Monte Carlo simulations in order to determine, by means of
microdosimetry calculations, tumour control probability (TCP) curves for treatments with 225 …

Background Metastatic castration-resistant prostate cancer (mCRPC) is associated with a
very unfavorable prognosis. At this advanced stage of the disease, there are several …